Crystalline acetylcholinesterase inhibitor forms A, B, C for neurodegenerative diseases
Summary
USPTO granted Patent US12590061B2 to Shanghai Institute of Materia Medica, Chinese Academy of Sciences covering crystalline forms A, B, and C of an acetylcholinesterase inhibitor compound (2-((1-(2-fluorobenzyl)-4-fluoropiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-1-indanone). The patent, filed November 24, 2020 as Application No. 17780449 with 10 claims, protects the stable, low-hygroscopicity crystalline forms used for preventing and treating neurodegenerative diseases.
What changed
The USPTO issued Patent US12590061B2 granting exclusive rights to Shanghai Institute of Materia Medica for three crystalline forms (A, B, C) of an acetylcholinesterase inhibitor compound. The patent protects the preparation method and pharmaceutical applications of these forms, which demonstrate high stability, low hygroscopicity, and absence of water or solvent. The compound targets neurodegenerative diseases through acetylcholinesterase inhibition.
Pharmaceutical companies and researchers developing similar acetylcholinesterase inhibitors should review this patent to assess freedom-to-operate implications for their drug development programs. Parties interested in licensing or challenging this patent should consult the full USPTO record and claims. No immediate compliance actions or deadlines are associated with this patent grant.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Crystalline form of acetylcholinesterase inhibitor and preparation method therefor and application thereof
Grant US12590061B2 Kind: B2 Mar 31, 2026
Assignee
SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
Inventors
Hong Liu, Yu Zhou, Haiyan Zhang, Yan Fu, Jian Li, Hualiang Jiang, Xican Tang, Kaixian Chen
Abstract
The present invention provides a crystalline form of an acetylcholinesterase inhibitor, a preparation method therefor and application thereof. Specifically, the crystalline form is crystalline form A, crystalline form B and crystalline form C of 2-((1-(2-fluorobenzyl)-4-fluoropiperidin-4-yl) methylene)-5, 6-dimethoxy-2, 3-dihydro-1-indanone. The crystalline form of the present invention does not contain water and solvent, has high stability and low hygroscopicity, is easy to process, and is very suitable for preparing drugs for preventing and/or treating neurodegenerative diseases.
CPC Classifications
A61P 25/00 A61P 25/28 C07D 211/38 C07B 2200/13
Filing Date
2020-11-24
Application No.
17780449
Claims
10
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.